Salvino is the first medicinal chemist to join Wistar’s staff, and his work to identify novel small molecule lead compounds provides a strong basis for collaboration with all Wistar researchers.
Salvino has more than 30 years of experience in drug discovery, including early stage hit-to-lead, lead optimization, and preclinical development where several drug candidates have successfully completed human clinical trials, including Entereg®, ADL-101, and Radezolid®. Prior to joining Wistar, Salvino was a professor in the Department of Pharmacology and Physiology at Drexel University College of Medicine. Before that, he held high level positions including vice president, senior director, and director in the biotechnology and pharmaceutical industries of Sterling Winthrop, Rhone-Poulenc Rorer, Aventis, Rib-X Pharmaceuticals, Adolor Corporation, and Cephalon.
Salvino received his Ph.D. in organic chemistry from Brown University and completed postdoctoral training in synthetic and medicinal chemistry at the University of Pennsylvania under the mentorship of K.C. Nicolaou and Ralph F. Hirschmann.
The Salvino Laboratory
